{"id":"NCT03598790","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-05","primaryCompletion":"2023-11-14","completion":"2023-11-14","firstPosted":"2018-07-26","resultsPosted":"2024-12-06","lastUpdate":"2025-01-14"},"enrollment":1353,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Moderate to Severe Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["UCB4940"]}],"arms":[{"label":"Bimekizumab dose regimen 1","type":"EXPERIMENTAL"},{"label":"Bimekizumab dose regimen 2","type":"EXPERIMENTAL"}],"summary":"This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).","primaryOutcome":{"measure":"Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)","timeFrame":"From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period","effectByArm":[{"arm":"Cohort A: BKZ 320 mg Q8W","deltaMin":97.83,"sd":null},{"arm":"Cohort A: BKZ 320 mg Q4W","deltaMin":179.68,"sd":null},{"arm":"Cohort A: Group A BKZ 320 mg Q8W","deltaMin":79.02,"sd":null},{"arm":"Cohort A: Group B BKZ 320 mg Q8W","deltaMin":77.11,"sd":null},{"arm":"Cohort A: Group B BKZ 320 mg Q4W/Q8W","deltaMin":73.78,"sd":null},{"arm":"Cohort B: PSO BKZ Total","deltaMin":244.08,"sd":null},{"arm":"Cohort B: EP BKZ Total","deltaMin":328.25,"sd":null},{"arm":"Cohort B: GPP BKZ Total","deltaMin":188.71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":189,"countries":["United States","Australia","Belgium","Canada","Germany","Hungary","Italy","Japan","Poland","Russia","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["35544084","36689515","37950894","38588819","39578348","40886218","40788331","36751950"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":1217},"commonTop":["Nasopharyngitis","Oral candidiasis","Corona virus infection","Upper respiratory tract infection","Urinary tract infection"]}}